Your browser doesn't support javascript.
loading
An intermediate-effect size variant in UMOD confers risk for chronic kidney disease.
Olinger, Eric; Schaeffer, Céline; Kidd, Kendrah; Elhassan, Elhussein A E; Cheng, Yurong; Dufour, Inès; Schiano, Guglielmo; Mabillard, Holly; Pasqualetto, Elena; Hofmann, Patrick; Fuster, Daniel G; Kistler, Andreas D; Wilson, Ian J; Kmoch, Stanislav; Raymond, Laure; Robert, Thomas; Eckardt, Kai-Uwe; Bleyer, Anthony J; Köttgen, Anna; Conlon, Peter J; Wiesener, Michael; Sayer, John A; Rampoldi, Luca; Devuyst, Olivier.
Affiliation
  • Olinger E; Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
  • Schaeffer C; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 3BZ, United Kingdom.
  • Kidd K; Molecular Genetics of Renal Disorders, Division of Genetics and Cell Biology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, 20132 Italy.
  • Elhassan EAE; Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC 27101.
  • Cheng Y; Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic.
  • Dufour I; Division of Nephrology, Beaumont General Hospital, 1297 Dublin, Ireland.
  • Schiano G; Department of Medicine, Royal College of Surgeons in Ireland, 1297 Dublin, Ireland.
  • Mabillard H; Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, D-79106 Freiburg, Germany.
  • Pasqualetto E; Faculty of Biology, University of Freiburg, D-79106 Freiburg, Germany.
  • Hofmann P; Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
  • Fuster DG; Division of Nephrology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
  • Kistler AD; Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
  • Wilson IJ; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 3BZ, United Kingdom.
  • Kmoch S; Renal Services, Newcastle Upon Tyne Hospitals National Health Service Trust, Newcastle upon Tyne NE7 7DN, United Kingdom.
  • Raymond L; Molecular Genetics of Renal Disorders, Division of Genetics and Cell Biology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, 20132 Italy.
  • Robert T; Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
  • Eckardt KU; Department of Medicine, Cantonal Hospital Frauenfeld, 8501 Frauenfeld, Switzerland.
  • Bleyer AJ; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE1 3BZ, United Kingdom.
  • Köttgen A; Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC 27101.
  • Conlon PJ; Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic.
  • Wiesener M; Genetics Department, Laboratoire Eurofins Biomnis, Lyon, 69007 France.
  • Sayer JA; Centre de Néphrologie et Transplantation Rénale, Centre Hospitalier Universitaire (CHU) la Conception, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, 13005 France.
  • Rampoldi L; Marseille Medical Genetics, Bioinformatics & Genetics, Unité Mixte de Recherche (UMR)_S910, Aix-Marseille Université, Marseille, 13005 France.
Proc Natl Acad Sci U S A ; 119(33): e2114734119, 2022 08 16.
Article in En | MEDLINE | ID: mdl-35947615
ABSTRACT
The kidney-specific gene UMOD encodes for uromodulin, the most abundant protein excreted in normal urine. Rare large-effect variants in UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD), while common low-impact variants strongly associate with kidney function and the risk of chronic kidney disease (CKD) in the general population. It is unknown whether intermediate-effect variants in UMOD contribute to CKD. Here, candidate intermediate-effect UMOD variants were identified using large-population and ADTKD cohorts. Biological and phenotypical effects were investigated using cell models, in silico simulations, patient samples, and international databases and biobanks. Eight UMOD missense variants reported in ADTKD are present in the Genome Aggregation Database (gnomAD), with minor allele frequency (MAF) ranging from 10-5 to 10-3. Among them, the missense variant p.Thr62Pro is detected in ∼1/1,000 individuals of European ancestry, shows incomplete penetrance but a high genetic load in familial clusters of CKD, and is associated with kidney failure in the 100,000 Genomes Project (odds ratio [OR] = 3.99 [1.84 to 8.98]) and the UK Biobank (OR = 4.12 [1.32 to 12.85). Compared with canonical ADTKD mutations, the p.Thr62Pro carriers displayed reduced disease severity, with slower progression of CKD and an intermediate reduction of urinary uromodulin levels, in line with an intermediate trafficking defect in vitro and modest induction of endoplasmic reticulum (ER) stress. Identification of an intermediate-effect UMOD variant completes the spectrum of UMOD-associated kidney diseases and provides insights into the mechanisms of ADTKD and the genetic architecture of CKD.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Insufficiency, Chronic / Uromodulin Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Document type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Insufficiency, Chronic / Uromodulin Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Document type: Article Affiliation country: Switzerland